Penbutolol | CAS#38363-40-5 | beta-blocker

MedKoo Cat#: 597704 | Name: Penbutolol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Penbutolol is a nonselective beta-blocker used as an antihypertensive and an antianginal agent.

Chemical Structure

Penbutolol

CAS#38363-40-5 (free base)

Theoretical Analysis

MedKoo Cat#: 597704

Name: Penbutolol

CAS#: 38363-40-5 (free base)

Chemical Formula: C18H29NO2

Exact Mass: 291.2198

Molecular Weight: 291.43

Elemental Analysis: C, 74.18; H, 10.03; N, 4.81; O, 10.98

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

38363-40-5 (free base) 38363-32-5 (sulfate)

Synonym

Penbutolol; HOE 893; HOE 893D; Betapressin; Levopenbutol; l-Penbutolol;

IUPAC/Chemical Name

(S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol

InChi Key

KQXKVJAGOJTNJS-HNNXBMFYSA-N

InChi Code

InChI=1S/C18H29NO2/c1-18(2,3)19-12-15(20)13-21-17-11-7-6-10-16(17)14-8-4-5-9-14/h6-7,10-11,14-15,19-20H,4-5,8-9,12-13H2,1-3H3/t15-/m0/s1

SMILES Code

O[C@@H](CNC(C)(C)C)COC1=CC=CC=C1C2CCCC2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 291.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ita KB, Popova IE. Influence of sonophoresis and chemical penetration enhancers on percutaneous transport of penbutolol sulfate. Pharm Dev Technol. 2016 Dec;21(8):990-995. Epub 2015 Sep 18. PubMed PMID: 26383739. 2: Haeringer E, Graml W, Rangoonwala B, Roessner M. Efficacy of penbutolol and a fixed combination of penbutolol with furosemide in the treatment of hypertension. Pharmatherapeutica. 1982;3(4):233-42. PubMed PMID: 7146039. 3: Schoenberger JA. Usefulness of penbutolol for systemic hypertension. Penbutolol Research Group. Am J Cardiol. 1989 Jun 1;63(18):1339-42. PubMed PMID: 2658525. 4: Graml E, Verho M, Rangoonwala B, Englert R, Häringer E, Pahnke K. Efficacy of penbutolol and a combination of a low dose of penbutolol with piretanide in the treatment of mild to moderate hypertension. Pharmatherapeutica. 1985;4(4):236-43. PubMed PMID: 3903788. 5: Brockmeier D, Hajdù P, Henke W, Mutschler E, Palm D, Rupp W, Spahn H, Verho MT, Wellstein A. Penbutolol: pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioligand binding. Eur J Clin Pharmacol. 1988;35(6):613-23. PubMed PMID: 2906875. 6: De Plaen JF, Vander Elst E, Van Ypersele de Strihou C. Penbutolol or hydrochlorothiazide once a day in hypertension. A controlled study with home measurements. Br J Clin Pharmacol. 1981 Aug;12(2):215-21. PubMed PMID: 7030372; PubMed Central PMCID: PMC1401847. 7: Lehr KH, Damm P, Fehlhaber HW, Hajdù P. Isolation, identification and in vitro synthesis of conjugates of penbutolol and its metabolites. Arzneimittelforschung. 1987 Nov;37(11):1222-4. PubMed PMID: 3440029. 8: Ita KB, Banga AK. In vitro transdermal iontophoretic delivery of penbutolol sulfate. Drug Deliv. 2009 Jan;16(1):11-4. doi: 10.1080/10717540802396976. PubMed PMID: 19555303. 9: Martínez Jordá R, Aguirre C, Calvo R, Rodríguez-Sasiaín JM, Erill S. Decrease in penbutolol central response as a cause of changes in its serum protein binding. J Pharm Pharmacol. 1990 Mar;42(3):164-6. PubMed PMID: 1974610. 10: Ochs HR, Hajdú P, Greenblatt DJ. Pharmacokinetics and dynamics of penbutolol in humans: evidence for pathway-specific stereoselective clearance. Klin Wochenschr. 1986 Jul 15;64(14):636-41. PubMed PMID: 3762014. 11: Meyer BH, Müller FO, Hundt HK, Grigoleit HG, Hajdu P, Heptner W. Penbutolol and furosemide in a fixed-dose combination-bio-equivalence of two formulations. S Afr Med J. 1981 Jun 13;59(25):891-3. PubMed PMID: 7015536. 12: Verho M, Färber G, Kirsten R, Nelson K. Effects of penbutolol on plasma atrial natriuretic peptide and antidiuretic hormone levels before and after exercise: a double-blind comparison against placebo. Pharmatherapeutica. 1989;5(5):320-8. PubMed PMID: 2526341. 13: Aguirre C, Trocóniz IF, Valdivieso A, Jiménez RM, González JP, Calvo R, Rodríguez-Sasiaín JM. Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: role of altered protein binding. Res Commun Mol Pathol Pharmacol. 1996 Apr;92(1):53-72. PubMed PMID: 8733828. 14: Vedin JA, Wilhelmsson C, Maass L, Peterson LE. Pharmacodynamic and pharmacokinetic study of oral and intravenous penbutolol. Eur J Clin Pharmacol. 1983;25(4):529-34. PubMed PMID: 6653649. 15: Müller FO, Hundt HK, Bromley PA, Torres J, Vanderbeke O. Single and divided doses of penbutolol. Clin Pharmacol Ther. 1979 May;25(5 Pt 1):528-35. PubMed PMID: 436357. 16: Sánchez C, Arnt J, Moltzen EK. The antiaggressive potency of (-)-penbutolol involves both 5-HT1A and 5-HT1B receptors and beta-adrenoceptors. Eur J Pharmacol. 1996 Feb 15;297(1-2):1-8. PubMed PMID: 8851159. 17: Bernard N, Cuisinaud G, Pozet N, Zech PY, Sassard J. Pharmacokinetics of penbutolol and its metabolites in renal insufficiency. Eur J Clin Pharmacol. 1985;29(2):215-9. PubMed PMID: 4076321. 18: Vander Elst E, Lawrence J, Rössner M, Mertens H. Penbutolol in hypertension, alone and in combination with furosemide. A long-term multicentre study. S Afr Med J. 1983 Jan 29;63(5):143-7. PubMed PMID: 6336854. 19: Kubik MM, Hanks GW. Single daily dose penbutolol in the treatment of hypertension: a double blind crossover comparison with propranolol. Eur J Clin Pharmacol. 1980 Jun;17(6):409-13. PubMed PMID: 6995132. 20: Heel RC, Brogden RN, Speight TM, Avery GS. Penbutolol: a preliminary review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs. 1981 Jul;22(1):1-25. PubMed PMID: 7261952.